Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alexandra Wagner-Bohn"'
Publikováno v:
Oncology Research and Treatment. 30:21-26
In noncommercial clinical drug research the implementation of the principles of Good Clinical Practice (GCP) has been criticized for introducing unnecessary bureaucracy at the expense of scientific activity, especially when small populations such as
Autor:
Joachim Gerss, Alexandra Wagner-Bohn, Joachim Boos, Joao Paolo Vieira Pinheiro, Clemens C. Stoffregen, M. Paulussen
Publikováno v:
Anti-Cancer Drugs. 17:859-864
The therapeutic benefit and side-effect profile of gemcitabine in adults with relapsed solid tumors is well known. So far, few data are available about its significance in pediatric relapsed solid tumors. To determine the efficacy and tolerability of
Autor:
Christian Rübe, Marlies Wienstroer, Joachim Boos, Alexandra Wagner-Bohn, Christina Mosler, Andreas Schuck, Georg Hempel, Normann Willich
Publikováno v:
Anti-Cancer Drugs. 14:417-422
Our aim was to assess the pharmacokinetics of a low-dose schedule of paclitaxel in combination with radiation therapy in patients with brain tumors. Eighteen patients received 20-50 mg/m2 paclitaxel as a 1-h infusion 18-24 h before radiation with 2 G
Autor:
Ursula Creutzig, Alexandra Wagner-Bohn, J. Ritter, Joachim Boos, Angelika Dübbers, Dirk Reinhardt, C Lanvers
Publikováno v:
Medical and Pediatric Oncology. 40:293-301
Background Due to severe side effects in virtually all children treated with a standard dose of 45 mg/m2/day all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) the AML-BFM study group reduced the dosage to 25 mg/m2/day. For the lac
Autor:
Joachim Boos, Alexandra Wagner-Bohn
Publikováno v:
BMC News and views. 4
Autor:
Claudia, Lanvers, Dirk, Reinhardt, Angelika, Dübbers, Alexandra, Wagner-Bohn, Ursula, Creutzig, Joerg, Ritter, Joachim, Boos
Publikováno v:
Medical and pediatric oncology. 40(5)
Due to severe side effects in virtually all children treated with a standard dose of 45 mg/m(2)/day all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) the AML-BFM study group reduced the dosage to 25 mg/m(2)/day. For the lack of da